POLYVALENT RECOMBINANT SWINE POX VIRUS Russian patent published in 2022 - IPC A61K39/12 C12N7/01 C12N15/86 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology, namely, to new recombinant swine pox viruses. Claimed are a recombinant swine pox virus (RSPV), a nucleic acid molecule containing the rSPV genome, a host cell containing rSPV, a method for producing rSPV, a composition containing an immunologically effective amount of rSPV, an application of rSPV, a vaccine set for immunisation of pigs, a method for immunisation or induction of an immune response in a non-human mammal.

EFFECT: claimed SPVs with two defects exhibit improved properties in terms of vaccination and can be used to create therapeutic agents or vaccines for treating any mammals, in particular, pigs.

25 cl, 11 dwg, 2 tbl, 5 ex